1129 Search Results for

Are “Bad Drug” Ads Bad for Patients?

August 16, 2018

Some 2 million Americans take blood thinners.  Nearly 30 million have diabetes. Tens of thousands more treat heartburn or cancer with medication prescribed by their doctor.  Chances are, these patients’ attention piques when they hear the medicine they take followed by “medical alert” or “warning” blaring from their television.  Many, including senior citizens, might even abandon their prescribed medicines out of fear.

How ICER Gets it Wrong

August 9, 2018

An influential calculation of how new drugs impact annual spending is flawed – and patients may be paying the price in reduced access to innovative medicine.

New Treatments Will Target Parkinson’s Patients’ “Off” Periods

August 7, 2018

Existing therapies help Parkinson’s patients control their tremors and stiffness – most of the time.  Now, new versions of the drug apormorphine could address breakthrough symptoms, which about 90 percent of patients experience during what’s known as “off” periods.  

Policymakers Increase Efforts to Eliminate Hepatitis C

August 2, 2018

Direct-acting antivirals, which provide about a 90 percent cure rate, can prevent cirrhosis and liver cancer, reducing the number of liver transplants needed, and minimizing disease transmission.  The initial list price of the drugs gave many insurers and health systems sticker shock, though market forces continue to drive down the price.

How Policymakers Can Stop Patients’ Co-Pay Surprise

July 31, 2018

Can policymakers prevent new co-pay accumulator programs from surprising patients at the pharmacy counter?  The short answer: yes. They have several options, in fact, according to a new overview of policy proposals from the Institute for Patient Access.  

2018 Infant Health Policy Summit

July 30, 2018

  Advocates cannot reach every infant or every family, acknowledged National Coalition for Infant Health Medical Director Mitchell Goldstein, MD,…

The Importation Question

July 24, 2018

To import, or not to import?  The question of whether to bring foreign, lower-priced versions of prescription drugs to the United States is back.